368 related articles for article (PubMed ID: 18929706)
1. Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia.
Barter P; Ginsberg HN
Am J Cardiol; 2008 Oct; 102(8):1040-5. PubMed ID: 18929706
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with statins and omega-3 fatty acids.
Nambi V; Ballantyne CM
Am J Cardiol; 2006 Aug; 98(4A):34i-38i. PubMed ID: 16919515
[TBL] [Abstract][Full Text] [Related]
3. Lipid effects of switching from prescription EPA+DHA (omega-3-acid ethyl esters) to prescription EPA only (icosapent ethyl) in dyslipidemic patients.
Crandell JR; Tartaglia C; Tartaglia J
Postgrad Med; 2016 Nov; 128(8):859-864. PubMed ID: 27684412
[TBL] [Abstract][Full Text] [Related]
4. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
5. Comparison of efficacy and safety of combination therapy with statins and omega-3 fatty acids versus statin monotherapy in patients with dyslipidemia: A systematic review and meta-analysis.
Choi HD; Chae SM
Medicine (Baltimore); 2018 Dec; 97(50):e13593. PubMed ID: 30558030
[TBL] [Abstract][Full Text] [Related]
6. Omega-3 fatty acid ethyl esters improve low-density lipoprotein subclasses without increasing low-density lipoprotein-cholesterol levels: A phase 4, randomized study.
Masuda D; Miyata Y; Matsui S; Yamashita S
Atherosclerosis; 2020 Jan; 292():163-170. PubMed ID: 31809985
[TBL] [Abstract][Full Text] [Related]
7. Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options.
Weintraub H
Atherosclerosis; 2013 Oct; 230(2):381-9. PubMed ID: 24075771
[TBL] [Abstract][Full Text] [Related]
8. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
9. Nonstatin therapies for management of dyslipidemia: a review.
Sando KR; Knight M
Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799
[TBL] [Abstract][Full Text] [Related]
10. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia.
Maki KC; McKenney JM; Reeves MS; Lubin BC; Dicklin MR
Am J Cardiol; 2008 Aug; 102(4):429-33. PubMed ID: 18678300
[TBL] [Abstract][Full Text] [Related]
11. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
Fazio S
Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
Davidson MH; Stein EA; Bays HE; Maki KC; Doyle RT; Shalwitz RA; Ballantyne CM; Ginsberg HN;
Clin Ther; 2007 Jul; 29(7):1354-67. PubMed ID: 17825687
[TBL] [Abstract][Full Text] [Related]
13. Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials.
Marston NA; Giugliano RP; Im K; Silverman MG; O'Donoghue ML; Wiviott SD; Ference BA; Sabatine MS
Circulation; 2019 Oct; 140(16):1308-1317. PubMed ID: 31530008
[TBL] [Abstract][Full Text] [Related]
14. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
Jacobson TA
Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969
[TBL] [Abstract][Full Text] [Related]
15. [Multimodal therapy of dyslipidemia].
Stahn A; Hanefeld M
Clin Res Cardiol Suppl; 2011 May; 6():10-6. PubMed ID: 22528173
[TBL] [Abstract][Full Text] [Related]
16. Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk.
Sharma RK; Singh VN; Reddy HK
Vasc Health Risk Manag; 2009; 5():793-9. PubMed ID: 19812691
[TBL] [Abstract][Full Text] [Related]
17. Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides.
Kedia AW; Lynch E
Postgrad Med; 2015; 127(8):869-73. PubMed ID: 26453247
[TBL] [Abstract][Full Text] [Related]
18. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
Reiner Z
Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
[TBL] [Abstract][Full Text] [Related]
19. Omega-3 carboxylic acids monotherapy and combination with statins in the management of dyslipidemia.
Benes LB; Bassi NS; Davidson MH
Vasc Health Risk Manag; 2016; 12():481-490. PubMed ID: 28003756
[TBL] [Abstract][Full Text] [Related]
20. Addition of omega-3 fatty acid and coenzyme Q10 to statin therapy in patients with combined dyslipidemia.
Tóth Š; Šajty M; Pekárová T; Mughees A; Štefanič P; Katz M; Spišáková K; Pella J; Pella D
J Basic Clin Physiol Pharmacol; 2017 Jul; 28(4):327-336. PubMed ID: 28541926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]